Tg Therapeutics (TGTX) Amortization of Deferred Charges (2011 - 2026)

Tg Therapeutics' Amortization of Deferred Charges history runs 11 years deep, the most recent figure standing at $300000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 1.32% year-over-year to $300000.0; the TTM figure through Mar 2026 stood at $1.2 million (down 76.92% YoY), while the FY2025 annual figure was $1.2 million, down 39.2% from the prior year.
• Amortization of Deferred Charges was $300000.0 for Q1 2026 at Tg Therapeutics, down from $304000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $4.0 million in Q3 2024 to a low of $300000.0 in Q1 2026.
• Historically, Amortization of Deferred Charges has averaged $669705.9 across 5 years, with a median of $461000.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges surged 566.67% in 2024, then plunged 92.4% in 2025.
• A 5-year view of Amortization of Deferred Charges shows it stood at $461000.0 in 2022, then jumped by 43.38% to $661000.0 in 2023, then tumbled by 53.4% to $308000.0 in 2024, then fell by 1.3% to $304000.0 in 2025, then dropped by 1.32% to $300000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $300000.0 (Q1 2026), $304000.0 (Q4 2025), and $304000.0 (Q3 2025), per Business Quant data.